Sara M. Tolaney, MD, MPH

Sara M Tolaney, MD is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School.

Articles

Abemaciclib Plus Adjuvant Endocrine Therapy in Breast Cancer

January 23rd 2023

Using the monarchE trial as a benchmark, experts in oncology discuss the use of abemaciclib with adjuvant endocrine therapy in patients with high-risk, early stage HR+ breast cancer.

Patient Profile 1: A 56-Year-Old Woman with Early HR+ Breast Cancer

January 16th 2023

Expert oncologists offer their initial impressions of a profile of a 56-year-old woman with early stage, HR+ breast cancer.

HR+ Breast Cancer: Incidence, Prognosis, and Risk Stratification

January 16th 2023

Sara Tolaney, MD, MPH, and Massimo Cristofanilli, MD, discuss factors that affect risk stratification of patients with HR+, HER2- breast cancer.

Updated Results of APHINITY at 8.4 Years Median Follow Up

November 17th 2022

Dr Sara M Tolaney reviews data from the APHINITY trial regarding the pertuzumab plus trastuzumab and chemotherapy treatment regimen for patients with HER2+ breast cancer.

Ongoing Clinical Trials With ADC Therapy in HR+ Metastatic Breast Cancer

November 1st 2022

Breast medical oncologists close out the program on HR+ metastatic breast cancer by highlighting ongoing clinical trials with antibody-drug conjugate therapy.

HR+ Metastatic Breast Cancer: What is the Role of Antibody-Drug Conjugates?

October 25th 2022

Centering discussion on antibody-drug conjugates in HR+ metastatic breast cancer, panelists consider the selection and use of these agents in practice.

HER2-Low Metastatic Breast Cancer and Use of Trastuzumab Deruxtecan

October 25th 2022

Centering their discussion on the HER2 low setting of HR+ metastatic breast cancer, medical oncologists review data behind trastuzumab deruxtecan therapy.

Treatment for HR+ Metastatic Breast Cancer After Progression on CDK4/6 Inhibitors

October 18th 2022

Shared insight on appropriate treatment options for patients with HR+ metastatic breast cancer following progression on CDK4/6 inhibitors.

HR+ Metastatic Breast Cancer: Continuing CDK4/6 Inhibition Beyond Progression

October 18th 2022

Expert panelists consider when it is appropriate to continue the use of CDK4/6 inhibitors beyond progression in HR+ metastatic breast cancer.

Interpreting Data With CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

October 11th 2022

In the context of recent clinical trials, experts share their perspective on the selection and use of CKD4/6 inhibitor therapy in patients with HR+ metastatic breast cancer.

Brief Review of SERM Therapy Data in HR+ Metastatic Breast Cancer

October 11th 2022

Closing out their review of endocrine therapy in HR+ metastatic breast cancer, panelists consider clinical trial data with selective estrogen receptor modulators [SERMs].

What is the Role of Oral SERD Therapy in HR+ Metastatic Breast Cancer?

October 4th 2022

Comprehensive insight to the development and use of selective estrogen receptor degraders [SERDs] in HR+ metastatic breast cancer treatment.

HR+ Metastatic Breast Cancer: Overview of the Current Treatment Landscape

October 4th 2022

Opening their discussion on the HR+ metastatic breast cancer treatment landscape, expert oncologists share a broad overview of treatment modalities in this setting.

Future Directions in the Management of HER2+ Breast Cancer

June 29th 2022

Before closing out the discussion on the management of HER2+ breast cancer, experts share their excitement on future treatment strategies.

Patient Profile 5: Strategies for Managing Elevated Liver Function Tests in Patients on the HER2CLIMB Regimen

June 22nd 2022

Experts consider how best to manage adverse events associated with the HER2CLIMB regimen in the setting of HER2+ metastatic breast cancer.

Patient Profile 4: Managing AEs in Patients Receiving Treatment for HER2+ BC

June 22nd 2022

A brief discussion on optimally managing adverse events while treating patients with HER2+ breast cancer.

Patient Profile 4: Strategies for Managing ILD in Patients Receiving Trastuzumab Deruxtecan

June 15th 2022

Sara Tolaney, MD, provides practical advice for managing interstitial lung disease in patients with metastatic HER2+ breast cancer.

Patient Profile 3: Treatment Sequencing in a Patient with metastatic HER2+ Breast Cancer

June 15th 2022

Shared insight on factors for selecting therapy in a patient with HER2+ metastatic breast cancer progressing through multiple lines of therapy.

Patient Profile 3: 43-Year-Old Woman With Metastatic Breast Cancer Progressing Through Multiple Lines of Therapy

June 8th 2022

Expert oncologist Rena Callahan, MD, shares a real-world clinical scenario of a 43-year-old woman with metastatic breast cancer who progressed through multiple lines of therapy.

Patient Profile 2: Treatment Sequencing in a Patient with Progressive Brain Metastases

June 8th 2022

Expert perspectives on use of trastuzumab deruxtecan in patients with HER2+ breast cancer who develop brain metastases.